Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes

Clinical and Experimental Rheumatology

Volumn 26, Issue 4, 2008, Pages 574-581

  Selvi, Enrico ^a   Lorenzini, Sauro ^a   Garcia Gonzalez, Estrella ^a   Maggio, Roberta ^a   Lazzerini, Pietro Enea ^b   Capecchi, Pier Leopoldo ^b   Balistreri, Epifania ^a   Spreafico, Adriana ^a   Niccolini, Silvia ^a   Pompella, Gerarda ^b   Natale, Maria Rita ^b   Guideri, Francesca ^b   Pasini, Franco Laghni ^b   Galeazzi, Mauro ^a   Marcolongo, Roberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Cannabinoids; Cytokines; Rheumatoid arthritis; Synoviocytes

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; JOINT PROSTHESIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SUPERNATANT; SYNOVIOCYTE; WESTERN BLOTTING;

AGED; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BENZOXAZINES; COHORT STUDIES; CYCLOHEXANOLS; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MORPHOLINES; NAPHTHALENES; OSTEOARTHRITIS, KNEE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SYNOVIAL MEMBRANE;

EID: 52649089192     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. PORTER AC, SAUER JM, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4.
2. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
3. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
4. COSTA B, GIAGNONI G, FRANKE C, TROVATO AE, COLLEONI M: Vanilloid TRPV 1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004; 143: 247-50.
5. BAKER CL, MCDOUGALL JJ: The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004; 142: 1361-7.
6. BEGG M, PACHER P, BATKAI S et al.: Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
7. BURSTEIN S: PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 2005; 77: 1674-84.
8. SIMONIN MA, BORDJI K, BOYAULT S et al.: PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 2002; 282: 125-33.
9. JIANG C, TING AT, SEED B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
10. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
11. AINOLA MM, MANDELIN JA, LILJESTROM MP, LI TF, HUKKANEN MV, KONTTINEN YT: Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1 beta. Clin Exp Rheumatol 2005; 23: 644-50.
12. TOLBOOM TC, ZHANG YH, HENRIQUEZ NV et al.: Fibroblast-like synoviocytes from patients with rheumatoid arthritis are more sensitive to apoptosis induced by the viral protein, apoptin, than fibroblast-like synoviocytes from trauma patients. Clin Exp Rheumatol 2006; 24: 142-7.
13. STEENVOORDEN MM, BANK RA, RONDAY HK, TOES RE, HUIZINGA TW, DEGROOT J Fibroblast-like synoviocyte-chondrocyte interaction in cartilage degradation. Clin Exp Rheumatol 2007; 25: 239-45.
14. MORITA Y, KASHIHARA N, YAMAMURA M et al.: Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA. Arthritis Rheum 1997; 40: 1292-7.
15. KRAAN MC, PATEL DD, HARINGMAN JJ et al.: The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001; 3: 65-71.
16. ZURIER RB, ROSSETTI RG, LANE JH, GOLDBERG JM, HUNTER SA, BURSTEIN SH: Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998; 41: 163-70.
17. ZURIER RB, ROSSETTI RG, BURSTEIN SH, BIDINGER B: Suppression of human monocyte interleukin-1 beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 2003; 65: 649-55.
18. LIU J, LI H, BURSTEIN SH, ZURIER RB, CHEN JD: Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol. 2003; 63: 983-92.
19. JOHNSON DR, STEBULIS JA, ROSSETTI RG, BURSTEIN SH, ZURIER RB: Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 2007; 100: 184-90.
20. MALFAIT AM, GALLILY R, SUMARIWALLA PF et al.: The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in marine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97: 9561-6.
21. SUMARIWALLA PF, GALLILY R, TCHILIBON S, FRIDE E, MECHOULAM R, FELDMANN M: A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50: 985-98.
22. DE JESUS ML, SALLES J, MEANA JJ, CALLADO LF: Characterization of CB1 cannabinoid receptor immunoreactivity in post-mortem human brain homogenates. Neuroscience 2006; 140: 635-43.
23. COFFEY RG, YAMAMOTO Y, SNELLA E, PROSS S: Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol 1996; 52: 743-51.
24. SACERDOTE P, MASSI P, PANERAI AE, PAROLARO D: In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 2000; 109: 155-63.
25. KLEIN TW: Cannabinoid-based drugs as antiinflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-11.
26. MBVUNDULA EC, BUNNING AR, RAINSFORD KD: Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem Pharmacol 2005; 69: 635-40.
27. SHENG WS, HU S, MIN X, CABRAL GA, LOKENSGARD JR, PETERSON PK: Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005; 49: 211-9.
28. MORMINA ME, THAKUR S, MOLLEMAN A, WHELAN CJ, BAYDOUN AR: Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol 2006; 540: 183-90.
29. MARTENS FM, RABELINK TJ, OP 'T ROODT J, DE KONING EJ, VISSEREN FL: TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 2006; 27: 1605-9.
30. CELI FS, SHULDINER AR: The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr Diab Rep 2002; 2: 179-85.
31. JANABI N: Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta (12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J Immunol 2002; 168: 4747-55.
32. DEMUTH DG, MOLLEMAN A: Cannabinoid signalling. Life Sci 2006; 78: 549-63.
33. PUFFENBARGER AR, BOOTHE AC, CABRAL GA: Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29: 58-69.
34. VOLIN MV, HUYNH N, KLOSOWSKA K, CHONG KK, WOODS JM: Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum 2007; 56: 2512-22.
35. SCHETT G, TOHIDAST-AKRAD M, SMOLEN JS et al.: Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
36. BLAKE DR, ROBSON P, HO M, JUBB RW, MCCABE CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 50-2.